Wealth Enhancement Advisory Services
LEXX icon

Wealth Enhancement Advisory Services’s Lexaria Bioscience LEXX Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio LEXX Stock Details LEXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,385
Closed -$29.9K – 3739
2025
Q3 		$29.9K Buy
2,385
+333
+16% +$4.83K ﹤0.01% 3480
2025
Q2 		$27.7K Sell
2,052
-12
-0.6% -$207 ﹤0.01% 3274
2025
Q1 		$52.9K Buy
2,064
+139
+7% +$3.54K ﹤0.01% 2842
2024
Q4 		$60.6K Buy
1,925
+1,003
+109% +$37K ﹤0.01% 2852
2024
Q3 		$42.2K Hold
922
– – ﹤0.01% 2629
2024
Q2 		$38.4K Buy
922
+234
+34% +$10.5K ﹤0.01% 2466
2024
Q1 		$37.5K Buy
+688
New +$26.3K ﹤0.01% 2356

Other funds holding LEXX

ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
BAM
Byrne Asset Management Kingston, New Jersey $185M AUM 41.05% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KF
Krilogy Financial St. Louis, Missouri $3.38B AUM 30.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wealth Enhancement Advisory Services's LEXX Position: Q4 2025 in Review

Wealth Enhancement Advisory Services sold out of Lexaria Bioscience (LEXX) in Q4 2025, closing a stake of 2,385 shares — an estimated $29.9K sold.

Wealth Enhancement Advisory Services first reported a position in LEXX in Q1 2024 and held it in 7 quarters. The position peaked at $60.6K in Q4 2024. 20 funds tracked by Wall St. Rank hold LEXX as of Q4 2025.

  • Wealth Enhancement Advisory Services reported no remaining Lexaria Bioscience position as of Q4 2025 after selling out during the quarter.
  • Wealth Enhancement Advisory Services sold 2,385 Lexaria Bioscience shares in Q4 2025, an estimated $29.9K.
  • Wealth Enhancement Advisory Services first reported a position in Lexaria Bioscience in Q1 2024 and held it in 7 quarters.
  • Wealth Enhancement Advisory Services's Lexaria Bioscience position peaked at $60.6K in Q4 2024.
  • 20 funds tracked by Wall St. Rank held Lexaria Bioscience as of Q4 2025.

Based on Wealth Enhancement Advisory Services's 13F filing for Q4 2025, filed 8 Jan 2026.